Peptide‐activated double‐negative T cells can prevent autoimmune type‐1 diabetes development

Authors:

Abstract
Autoimmune diseases may develop because of defective maturation, activation, differentiation and function of regulatory T cells. Previous studies have shown that exposure to donor antigen activates peripheral TCRαβ+CD3+CD4–CD8–NK1.1–, double‐negative (DN) T cells, which specifically suppress anti‐donor T cells and enhance survival of skin and heart grafts from allogeneic and xenogeneic donors. However, the role of DN T cells in preventing T cell‐mediated autoimmune disease is unknown. Here, we analyzed the ability of DN T cells to recognize peptides expressed on self MHC and to suppress peptide‐reactive CD8+ T cells, using the P14 mouse model that expresses a transgenic TCR specific for gp33 peptide presented on self MHC class I‐Db. We found that injection of gp33 peptide resulted in increased DN and decreased CD8+ T cell numbers in the lymph nodes when compared to untreated mice. Injection of gp33, but not TCR‐non‐specific AV peptide, increased expression of T cell activation markers on DN T cells. Moreover, gp33‐activated DN T cells suppressed proliferation of syngeneic CD8+ T cells via killing activated CD8+ T cells in an antigen‐specific fashion in vitro. Furthermore, transferring gp33‐activated DN T cells inhibited the development of autoimmune diabetes, suggesting that DN T cells may provide a novel therapy for T cell‐mediated autoimmune diseases.

This publication has 30 references indexed in Scilit: